Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Depreciation & Amortization (CF) (2016 - 2025)

Marimed (MRMD) has disclosed Depreciation & Amortization (CF) for 10 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 4.07% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Dec 2025, up 2.52% year-over-year, with the annual reading at $8.1 million for FY2025, 2.52% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $2.1 million at Marimed, down from $2.1 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $2.2 million in Q4 2024, with the low at $462000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.4 million, with a median of $1.4 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 96.55% in 2024, then decreased 6.76% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $600682.0 in 2021, then soared by 60.32% to $963000.0 in 2022, then surged by 77.67% to $1.7 million in 2023, then grew by 26.3% to $2.2 million in 2024, then decreased by 4.07% to $2.1 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $2.1 million, $2.1 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.